Asia Pacific Cell and Gene Therapy Biomanufacturing Market to Grow with a CAGR of 16.25% through 2028
Surge in research and development activities is expected to drive the Asia
Pacific Cell and Gene Therapy Biomanufacturing Market growth in the forecast
period, 2024-2028.
According to TechSci Research report, “Asia Pacific
Cell and Gene Therapy Biomanufacturing Market – By Country, Competition,
Forecast and Opportunities, 2018-2028F”, the Asia Pacific Cell and Gene
Therapy Biomanufacturing Market stood at USD1.73 billion in 2022 and is
anticipated to grow with a CAGR of 16.25% in the forecast period, 2023-2028. The
initiatives taken by government based on cell and gene therapy biomanufacturing
has led to favorable market conditions for the Asia Pacific Cell and Gene
Therapy Biomanufacturing Market. Several factors contribute to the growth of
various cell and gene therapy biomanufacturing market products.
AusBiotech, the
leading biotechnology industry association in Australia, has recently unveiled
a comprehensive blueprint aimed at establishing a seamless and integrated value
chain encompassing the entire lifecycle of cell and gene therapies. This
groundbreaking initiative encompasses the key stages of discovery, development,
manufacture, and distribution, and is set to revolutionize the field by
accelerating the translation of cutting-edge research into real-world therapies
that can transform patients' lives.
With its strong
emphasis on policy and advocacy work, AusBiotech is actively engaged in
productive discussions with the Australian Federal Government to drive support
and foster an enabling environment for the advancement of cell and gene
therapies. This collaborative approach is crucial in realizing the full
potential of these innovative treatments and ensuring their accessibility to
patients in need.
Browse over XX
market data Figures spread through XX Pages and an in-depth TOC on "Asia Pacific Cell and Gene Therapy Biomanufacturing Market”
The recent surge
in research and development (R&D) activities can be attributed directly to
the pressing global health challenges and the growing demand for advanced
therapeutics. In particular, the ongoing COVID-19 pandemic has highlighted the
critical need to expedite the development of innovative therapies and vaccines.
This sense of urgency has not only intensified R&D efforts but has also
significantly bolstered activities in the field of cell and gene therapy
biomanufacturing. With the aim of addressing the unmet medical needs and
combating various diseases, this increased focus on R&D is paving the way
for groundbreaking advancements in the field, offering hope for improved
healthcare outcomes and a brighter future.
The Asia Pacific
Cell and Gene Therapy Biomanufacturing Market is segmented into equipment,
application, regional distribution, and company.
Based on its equipment, the bioreactors/fermenters segment
held the largest share in the market. The revenues generated by sales of
bioreactors and fermenters used for manufacturing antibodies contribute
significantly to the current market. Antibodies, as a crucial component of many
cell and gene therapies (CGTs), underscore the essential role of bioreactors
and fermenters in the production of these life-changing therapies. With the
increasing demand for CGTs, the need for efficient and scalable bioreactor and
fermenter technologies becomes even more pronounced. These advanced systems
provide a controlled environment for the growth and cultivation of cells,
ensuring high-quality and consistent production of antibodies for therapeutic
applications.
As the field of biomanufacturing continues to evolve,
the continuous improvement and innovation in bioreactor and fermenter
technologies are anticipated to drive further advancements in CGTs, opening new
possibilities for the treatment of various diseases.
Based on country, China segment is expected to grow
during the forecast period.
In recent years, China, along with several other
countries in the Asia Pacific region, has been grappling with a significant
rise in the prevalence of chronic diseases. The burden of these conditions has
prompted a surge in the exploration and application of innovative treatment
approaches. Among the most promising are cell and gene therapies, which hold
immense potential in addressing these complex health challenges. As a result,
there has been an escalating demand for these advanced therapies, spurring the
expansion of the cell and gene therapy biomanufacturing market within the
country. This trend reflects a concerted effort to meet the growing healthcare
needs of the population and advance the field of personalized medicine, making
China a key player in the global landscape of regenerative medicine.
Major companies operating in Asia Pacific Cell and
Gene Therapy Biomanufacturing Market are:
- Becton, Dickinson and Company
- Bio-Rad Laboratories, Inc.
- Bio-Techne Corporation
- Danaher Corporation
- Endress+Hauser Group Services
AG (Analytik Jena GmbH)
- General Electric Company
- Getinge AB
- Infors AG
- Lonza Group Ltd
- Merck KGaA
Download Free Sample Report
Customers can also request for 10%
free customization on this report
“Growing application of cell and gene therapy biomanufacturing
in various end user industries are key drivers of the cell and gene therapy biomanufacturing
market. Growth in competitive landscape and presence of well-established companies
in the market who are dedicated to enhance their productivity of cell and gene therapy
biomanufacturing with every passing year are anticipated to register an
impressive growth to Asia Pacific Cell and Gene Therapy Biomanufacturing Market
in the forecast period.,” said Mr. Karan Chechi, Research Director with TechSci
Research, a research-based management consulting firm.
“Asia Pacific Cell and Gene Therapy Biomanufacturing Market
By Equipment (Bioreactors/Fermenters, Mixing Systems, Cell Counters, Cell
Sorters, Centrifuges, Incubators, Biosafety Cabinets, Freezers, PCR Systems,
Transfection Systems, Storage Tanks, Others), By Application (Formulation and
Hydration, Cell Culture Processing, Separation and Filtration, Others), By Country, By
Competition Forecast & Opportunities, 2018-2028F”, has evaluated
the future growth potential of Asia Pacific Cell and Gene Therapy
Biomanufacturing Market and provides statistics & information on market
size, structure, and future market growth. The report intends to provide
cutting-edge market intelligence and help decision makers take sound investment
decisions. Besides, the report also identifies and analyzes the emerging trends
along with essential drivers, challenges, and opportunities in Asia Pacific
Cell and Gene Therapy Biomanufacturing Market.
Contact
TechSci Research LLC
420 Lexington Avenue, Suite 300,
New York, United States- 10170
Tel: +1-332-258-6602
Email: [email protected]
Website: www.techsciresearch.com